Authors: McMurray, J Cohen-Solal, A Dietz, R Eichhorn, E Erhardt, L Hobbs, R Maggioni, A Pina, I Soler-Soler, J Swedberg, K

Citation: J. Mcmurray et al., Practical recommendations for the use of ACE inhibitors, beta-blockers andspironolactone in heart failure: putting guidelines into practice, EUR J HE FA, 3(4), 2001, pp. 495-502

Authors: Baruch, L Patacsil, P Hameed, A Pina, I Loh, E

Citation: L. Baruch et al., Pharmacodynamic effects of milrinone with and without a bolus loading infusion, AM HEART J, 141(2), 2001, pp. 266-266

Authors: Cuffe, MS Califf, RM Adams, KF Bourge, RC Colucci, W Massie, B O'Connor, CM Pina, I Quigg, R Silver, M Robinson, LA Leimberger, JD Gheorghiade, M

Citation: Ms. Cuffe et al., Rationale and design of the OPTIME CHF trial: Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure, AM HEART J, 139(1), 2000, pp. 15-22

Authors: Jaski, BE Lingle, RJ Kim, J Branch, KR Goldsmith, R Johnson, MR Lahpor, JR Icenogle, TB Pina, I Adamson, R Favrot, LK Dembitsky, WP

Citation: Be. Jaski et al., Comparison of functional capacity in patients with end-stage heart failurefollowing implantation of a left ventricular assist device versus heart transplantation: Results of the experience with left ventricular assist device with exercise trial, J HEART LUN, 18(11), 1999, pp. 1031-1040

Authors: Pina, I

Citation: I. Pina, FDA panel votes against approval for bivalirudin, CIRCULATION, 99(10), 1999, pp. 1277-1277